- United States
- /
- Medical Equipment
- /
- NasdaqCM:NSPR
InspireMD Full Year 2024 Earnings: US$0.76 loss per share (vs US$0.82 loss in FY 2023)
InspireMD (NASDAQ:NSPR) Full Year 2024 Results
Key Financial Results
- Revenue: US$7.01m (up 13% from FY 2023).
- Net loss: US$32.0m (loss widened by 61% from FY 2023).
- US$0.76 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
InspireMD Earnings Insights
Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 3.1% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with InspireMD (at least 1 which can't be ignored), and understanding these should be part of your investment process.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NSPR
InspireMD
A medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific.
Flawless balance sheet low.
Similar Companies
Market Insights
Community Narratives


